Quality versus quantity of life with cabozantinib and sunitinib in advanced kidney cancer

Cabozantinib and sunitinib are both drugs that block the development of blood vessels to supply the tumour and are called vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors (TKIs). These drugs are used to treat patients with advanced kidney cancer. Clinical trials have shown that cabozantinib is better at extending survival than sunitinib, giving patients […]

read more

ESMO Virtual 2020: Quality of life impact of immune checkpoint inhibitors

Immune checkpoint inhibitors have changed the way renal cell carcinoma (RCC) is treated and may improve quality of life. During a presentation at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 last week the results from a large analysis of the use of immune checkpoint inhibitors in different cancers was presented. The study […]

read more

Survivorship and immune checkpoint inhibitors

In a study reported in the August issue of the European Journal of Cancer, a group of American investigators reported findings from patients with melanoma, renal cell carcinoma (RCC) and non-small cell lung cancer (NSCLC) who survived longer than two years after treatment with PD-1 and PD-L1 inhibitors (immune checkpoint inhibitors). In conclusion, most patients […]

read more

Quality of life worse for cancer patients during COVID-19 pandemic

A paper published in Psycho-Oncology earlier this month suggests that patients with stage III and IV cancer have worse quality of life during the COVID-19 pandemic. Researchers from Lodz in Poland examined the quality of life of 238 patients with different types of stage III and IV cancer who were undergoing chemotherapy. Data from these patients […]

read more

Atezolizumab alone or in combination with bevacizumab for untreated metastatic kidney cancer

This paper reports patient-reported outcomes from the phase 2 IMmotion150 study to assess the safety and efficacy of atezolizumab alone or in combination with bevacizumab versus sunitinib in 305 untreated metastatic renal cell carcinoma (RCC) patients. For all patients in the study, objective response rates were 25%, 32%, and 29% for atezolizumab alone, atezolizumab plus […]

read more

Integrative oncology: using evidence-based medicine to improve patient outcomes and quality of life

A recent article published in Cancer Therapy Advisor describes what is meant by ‘integrative oncology’ and how evidence based medicine can be used to improve patient outcomes and quality of life. Cancer is among the leading causes of death worldwide, and new cases of cancer may rise to 23.6 million per year by 2030. However, […]

read more

Palliative care and survivorship

Although the following article from Cancer Therapy Advisor is written from a US perspective, a lot of what is discussed is relevant to the UK and the National Health Service. Over recent years, palliative care has evolved to include symptom management, management of psychosocial and spiritual needs, coping support, information about the disease and treatment, medical […]

read more

Patient-reported outcomes for atezolizumab plus bevacizumab combination

Patient-reported outcomes from the phase 3 IMmotion151 study, which assessed the atezolizumab plus bevacizumab combination versus sunitinib in metastatic renal cell carcinoma (RCC) patients, were presented at the 2018 American Society of Clinical Oncology (ASCO) annual meeting in Chicago this week. In the IMmotion151 clinical trial, the combination of atezolizumab plus bevacizumab improved progression-free survival […]

read more

Quality of life outcomes similar for cabozantinib and everolimus

Data from the phase 3 METEOR trial published in the Journal of Clinical Oncology recently show that treatment of advanced kidney cancer patients with cabozantinib resulted in similar quality of life (QoL) outcomes as for patients treated with everolimus. Cabozantinib also improved progression-free survival (PFS), overall survival (OS), and overall response rate (ORR) compared with everolimus. The […]

read more
Showing all 9 results
  TOP